Analyst Estimates: Here's What Brokers Think Of Tango Therapeutics, Inc. (NASDAQ:TNGX) After Its First-Quarter Report

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. (NASDAQ:TNGX), given that the company fell short of expectations when it released its first-quarter results last week. E

Simply Wall StMay 11 20:21

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)

TipRanksMay 10 13:30

Tango Therapeutics Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Tango Therapeutics Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow JonesMay 9 19:26

Buy Rating Affirmed for Tango Therapeutics on Promising PRMT5 Inhibitors and Strong Financials

TipRanksMay 9 18:37

Tango Therapeutics (TNGX) Gets a Buy From Barclays

TipRanksMay 9 15:26

Tango Therapeutics' Cash Position Of $344M As Of March 31, 2024; Cash Runway Into Late 2026 Expected

Tango Therapeutics' Cash Position Of $344M As Of March 31, 2024; Cash Runway Into Late 2026 Expected

BenzingaMay 8 19:36